WASHINGTON - Tysabri could be coming back, at least in a limited capacity. That’s the growing consensus among many industry observers about the once heralded multiple sclerosis drug, which was pulled from the market a year ago after it was linked to a pair of deaths. (BioWorld Today)
WASHINGTON - Tysabri could be coming back, at least in a limited capacity. That’s the growing consensus among many industry observers about the once heralded multiple sclerosis drug, which was pulled from the market a year ago after it was linked to a pair of deaths. (BioWorld Today)
The FDA approved Rituxan (rituximab) for rheumatoid arthritis, broadening the therapeutic antibody’s label and potentially its revenue. (BioWorld Today)
